Controlled Trial of Interleukin-2 Infusions in Patients Infected with the Human Immunodeficiency Virus
Authors:
- Susan VogelSVSusan Vogel
- Jeffrey M. AlbertJAJeffrey M. Albert
- Judith FalloonJFJudith Falloon
- Richard T. Jr. DaveyRDRichard T. Jr. Davey
- Robert E. WalkerRWRobert E. Walker
- Michael A. PolisMPMichael A. Polis
- Katherine SpoonerKSKatherine Spooner
- Julia A. MetcalfJMJulia A. Metcalf
- Michael BaselerMBMichael Baseler
- Gwendolyn FyfeGFGwendolyn Fyfe
- H. Clifford LaneHLH. Clifford Lane
- 31 October 1996
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 335 (18) , 1350-1356
Abstract
Interleukin-2 is a cytokine that regulates the proliferation and differentiation of lymphocytes. In preliminary studies, intermittent infusions of interleukin-2 led to increases in CD4 counts in patients with human immunodeficiency virus (HIV) infection and more than 200 CD4 cells per cubic millimeter. We conducted a controlled study to evaluate the long-term effects of such therapy on both CD4 counts and the viral burden.Keywords
This publication has 21 references indexed in Scilit:
- Alterations in the Immune Response of Human Immunodeficiency Virus (HIV)-Infected Subjects Treated with an HIV-Specific Protease Inhibitor, RitonavirThe Journal of Infectious Diseases, 1996
- Immune-based therapies in HIV infectionAIDS, 1996
- A Preliminary Study of Ritonavir, an Inhibitor of HIV-1 Protease, to Treat HIV-1 InfectionNew England Journal of Medicine, 1995
- A Short-Term Study of the Safety, Pharmacokinetics, and Efficacy of Ritonavir, an Inhibitor of HIV-1 ProteaseNew England Journal of Medicine, 1995
- Quantitation of HIV-1 RNA in Plasma Predicts Outcome after SeroconversionAnnals of Internal Medicine, 1995
- Host-Directed and Immune-Based Therapies for Human Immunodeficiency Virus InfectionAnnals of Internal Medicine, 1995
- Immune-Based Therapeutics: Scientific Rationale and the Promising Approaches to the Treatment of the Human Immunodeficiency Virus-Infected IndividualClinical Infectious Diseases, 1993
- Prolonged immunostimulatory effect of low-dose polyethylene glycol interleukin 2 in patients with human immunodeficiency virus type 1 infection.Journal of Experimental Medicine, 1993
- Efficacy of Low Doses of the Polyethylene Glycol Derivative of Interleukin-2 in Modulating the Immune Response of Patients with Human Immunodeficiency Virus Type 1 InfectionThe Journal of Infectious Diseases, 1993
- Interleukin-2: Inception, Impact, and ImplicationsScience, 1988